The FDA approved Lupin's generic pitolisant tablets as bioequivalent to WAKIX, and approved Harmony Biosciences' WAKIX for pediatric cataplexy, making it the first non-controlled treatment for both pediatric and adult narcolepsy patients.
The FDA has approved Harmony Biosciences' Wakix (pitolisant) for treating cataplexy in pediatric patients aged 6 years and older with narcolepsy, making it the first non-scheduled treatment for both pediatric and adult narcolepsy patients with or without cataplexy.
The FDA has approved pitolisant tablets for treating cataplexy in pediatric patients aged 6 and older with narcolepsy, making it the only non-scheduled therapy approved for both pediatric and adult narcolepsy patients with or without cataplexy.
Eli Lilly's Retevmo (selpercatinib) demonstrated statistically significant event-free survival improvement in the Phase III LIBRETTO-432 trial for early-stage RET fusion-positive non-small cell lung cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02068170 |
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital |
COMPLETED | |
| NCT02043925 |
QT-prolongation in Psychiatric Hospitals |
COMPLETED | |
| NCT02043912 |
Drug Interactions With Risk of QT-prolongation in a General Hospital |
COMPLETED |
